NUMI Fundamental Analysis - NUMINUS WELLNESS INC

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to NUMI. NUMI was compared to 30 industry peers in the Pharmaceuticals industry. NUMI has a bad profitability rating. Also its financial health evaluation is rather negative. NUMI is valued quite expensive, but it does show an excellent growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NUMI has reported negative net income.

In the past year NUMI has reported a negative cash flow from operations.

In the past 5 years NUMI always reported negative net income.

In the past 5 years NUMI always reported negative operating cash flow.

1.2 Ratios

NUMI has a worse Return On Assets (-213.24%) than 90.91% of its industry peers.

NUMI's Return On Equity of -644.74% is on the low side compared to the rest of the industry. NUMI is outperformed by 81.82% of its industry peers.

		Industry Rank	Sector Rank
ROA	-213.24%
ROE	-644.74%
ROIC	N/A

ROA(3y)-79.64%

ROA(5y)-255.28%

ROE(3y)-118.38%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

NUMI has a Gross Margin (32.02%) which is in line with its industry peers.

NUMI's Gross Margin has improved in the last couple of years.

The Profit Margin and Operating Margin are not available for NUMI so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	32.02%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y52.27%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NUMI does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for NUMI has been increased compared to 1 year ago.

The debt/assets ratio for NUMI is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -13.73, we must say that NUMI is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -13.73, NUMI is not doing good in the industry: 81.82% of the companies in the same industry are doing better.

NUMI has a Debt/Equity ratio of 0.95. This is a neutral value indicating NUMI is somewhat dependend on debt financing.

NUMI's Debt to Equity ratio of 0.95 is on the low side compared to the rest of the industry. NUMI is outperformed by 78.79% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.95
Debt/FCF	N/A
Altman-Z	-13.73

ROIC/WACCN/A

WACC8.99%

2.3 Liquidity

A Current Ratio of 1.40 indicates that NUMI should not have too much problems paying its short term obligations.

With a Current ratio value of 1.40, NUMI perfoms like the industry average, outperforming 51.52% of the companies in the same industry.

NUMI has a Quick Ratio of 1.40. This is a normal value and indicates that NUMI is financially healthy and should not expect problems in meeting its short term obligations.

NUMI has a better Quick ratio (1.40) than 60.61% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.4
Quick Ratio	1.4

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NUMI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.67%, which is quite impressive.

NUMI shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.69%.

Measured over the past years, NUMI shows a very strong growth in Revenue. The Revenue has been growing by 197.54% on average per year.

EPS 1Y (TTM)37.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%35.87%

Revenue 1Y (TTM)22.69%

Revenue growth 3Y197.54%

Revenue growth 5YN/A

Sales Q2Q%-27.88%

3.2 Future

Based on estimates for the next years, NUMI will show a very strong growth in Earnings Per Share. The EPS will grow by 29.53% on average per year.

Based on estimates for the next years, NUMI will show a very strong growth in Revenue. The Revenue will grow by 22.63% on average per year.

EPS Next Y58.33%

EPS Next 2Y38.44%

EPS Next 3Y25.99%

EPS Next 5Y29.53%

Revenue Next Year-18.04%

Revenue Next 2Y-0.45%

Revenue Next 3Y11.96%

Revenue Next 5Y22.63%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NUMI. In the last year negative earnings were reported.

Also next year NUMI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

NUMI's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y38.44%

EPS Next 3Y25.99%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NUMI!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NUMINUS WELLNESS INC

TSX:NUMI (1/29/2025, 7:00:00 PM)

0.05

+0.02 (+42.86%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)01-13 2025-01-13

Earnings (Next)N/A N/A

Inst Owners2.66%

Inst Owner ChangeN/A

Ins Owners3.55%

Ins Owner ChangeN/A

Market Cap16.12M

Revenue(TTM)26.05M

Net Income(TTM)-29.86M

Analysts82.86

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.62
P/FCF	N/A
P/OCF	N/A
P/B	3.48
P/tB	3.48
EV/EBITDA	N/A

EPS(TTM)-0.11

EYN/A

EPS(NY)-0.01

Fwd EYN/A

FCF(TTM)-0.05

FCFYN/A

OCF(TTM)-0.05

OCFYN/A

SpS0.08

BVpS0.01

TBVpS0.01

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-213.24%
ROE	-644.74%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	32.02%
FCFM	N/A

ROA(3y)-79.64%

ROA(5y)-255.28%

ROE(3y)-118.38%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y52.27%

GM growth 5YN/A

F-Score2

Asset Turnover1.86

Health

		Industry Rank	Sector Rank
Debt/Equity	0.95
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	1.51%
Cap/Sales	0.14%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.4
Quick Ratio	1.4
Altman-Z	-13.73

F-Score2

WACC8.99%

ROIC/WACCN/A

Cap/Depr(3y)61.7%

Cap/Depr(5y)N/A

Cap/Sales(3y)21.09%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)37.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%35.87%

EPS Next Y58.33%

EPS Next 2Y38.44%

EPS Next 3Y25.99%

EPS Next 5Y29.53%

Revenue 1Y (TTM)22.69%

Revenue growth 3Y197.54%

Revenue growth 5YN/A

Sales Q2Q%-27.88%

Revenue Next Year-18.04%

Revenue Next 2Y-0.45%

Revenue Next 3Y11.96%

Revenue Next 5Y22.63%

EBIT growth 1Y24.8%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year52.23%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y34.48%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y31.26%

OCF growth 3YN/A

OCF growth 5YN/A

NUMINUS WELLNESS INC / NUMI.CA FAQ

What is the ChartMill fundamental rating of NUMINUS WELLNESS INC (NUMI.CA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to NUMI.CA.

What is the valuation status of NUMINUS WELLNESS INC (NUMI.CA) stock?

ChartMill assigns a valuation rating of 1 / 10 to NUMINUS WELLNESS INC (NUMI.CA). This can be considered as Overvalued.

Can you provide the profitability details for NUMINUS WELLNESS INC?

NUMINUS WELLNESS INC (NUMI.CA) has a profitability rating of 1 / 10.

NUMINUS WELLNESS INC (NUMI.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

NUMINUS WELLNESS INC / NUMI.CA FAQ

What is the ChartMill fundamental rating of NUMINUS WELLNESS INC (NUMI.CA) stock?

What is the valuation status of NUMINUS WELLNESS INC (NUMI.CA) stock?

Can you provide the profitability details for NUMINUS WELLNESS INC?